Novartis Pharmaceuticals Canada Inc.
Registration:
40
of
40
(2025-04-30
to
present)
Details Regarding the Identified Subject Matter
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical Services Division will be making future funding decisions.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Hospitals
|
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative treatments for BC citizens that require access to these treatments, through various BC government funded programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Hospitals
|